Hunters Allenn 

201 posts

Hunters Allenn  banner
Hunters Allenn 

Hunters Allenn 

@Hunterallenn4

Stock Screener| Gap Fill Setups | Volume Breakouts| low floater finder| Memes included! Real-time levels, pivots & high-probability moves. NFA. 📈🚀TN- Go Vols

Johnson City, TN Katılım Eylül 2017
264 Takip Edilen4 Takipçiler
Hunters Allenn  retweetledi
Hunter Allen
Hunter Allen@HunterAllen4·
Okay I’ll say it. This dude has 52k followers. I know a lot are/were friends. I know he was being past tense respected on here, but how anyone could do anything but unfollow and block is crazy after this. I work my asssssss off on here. And I know plenty others who do too. And the ones he hurt, probably his friends at the time he hurt bad. And telling people to not sub to them, crazy work. The trust is gone. The honesty is gone. He should be gone. He Straight made other accounts and stole paid subs content from two other creators that most are aware of by now. X bans and suspends these other accounts for everything. People get kicked for far less. Zero tolerance Credibility gone But he’s gonna be allowed to still post? Ban.
English
37
6
100
8.1K
Hunters Allenn  retweetledi
Hunter Allen
Hunter Allen@HunterAllen4·
$LXFR Still not a sole on X or anywhere talking about IT. A day when space stocks are falling off a cliff too. She’s up They don’t disclose partners. But why no one hasn’t looked in to them I don’t know. $RKLB $LMT $LUNR $LHX $SPCX +4% Keep eyes 👀
Hunter Allen tweet mediaHunter Allen tweet media
Hunter Allen@HunterAllen4

$LXFR Space x IPO coming, let’s talk COPVs. Also close to breaking 3 year resistance of 17.90. A hidden bottleneck sitting inside multiple long-term growth themes. All these space stocks use COPVs. $RKLB $ASTS $LUNR $RDW $BA $LMT $PL $SPCE Repost. Bookmark. Subscribe to support. Almost nobody talks about $LXFR. That’s what makes it interesting. The company is one of the world’s largest and most experienced manufacturers of Composite Overwrapped Pressure Vessels (COPVs), with more than 70 million cylinders operating globally across aerospace, defense, medical, industrial gas, first responder, and alternative fuel markets. These aren’t commodity products. They’re highly engineered, mission-critical components that often become bottlenecks in supply chains where reliability and certifications matter more than price. The numbers don’t look explosive on the surface. But underneath, the story is improving. Q1 2026 revenue came in at $83.9M. Sales declined year-over-year largely because of portfolio changes, customer timing, and the ongoing transition following the Graphic Arts divestiture. However, adjusted EBITDA increased 8.8% YoY. Adjusted EPS grew 17.4% YoY. Gross margins expanded significantly. That’s important because 2026 appears to be a transition year. Management has repeatedly pointed investors toward 2027 as the year where multiple growth drivers begin contributing simultaneously. The biggest catalyst may be what happens after the Riverside consolidation, Saxonburg Powder Center of Excellence, and other operational optimization projects are fully completed. Those projects are already helping margins. By 2027 they should provide a full year of benefits. Luxfer operates across several attractive niche markets. Its Gas Cylinders segment supplies COPVs and high-pressure storage solutions for aerospace, defense, medical oxygen, SCBA firefighting systems, industrial gases, hydrogen transportation, CNG infrastructure, and space applications. Its Elektron segment supplies advanced magnesium alloys and specialty materials used across aerospace, defense, automotive, and industrial markets. Both businesses benefit from long-term secular demand trends. The broader COPV market is expected to grow significantly throughout the decade as lightweight pressure storage becomes increasingly important across aerospace, hydrogen, defense, and industrial applications. Luxfer already sits directly inside those supply chains. That’s where backlog visibility and end-market exposure become important. The SCBA opportunity alone could create a multi-year replacement cycle as municipalities upgrade aging equipment. Meanwhile, aerospace and defense demand continues providing visibility into future orders. This is where the valuation disconnect starts becoming noticeable. $HXL carries a market cap above $4B. $ATI carries a market cap above $12B. $RKLB carries a market cap above $15B. $AVAV carries a market cap above $20B. Many hydrogen and aerospace suppliers trade at substantially higher valuation multiples. $LXFR sits around $456M. Not $5B. Not $10B. Not $20B. That’s where things could get interesting. Management has openly discussed that the Elektron and Gas Cylinders businesses have limited strategic synergies. The company continues evaluating strategic alternatives after completing the Graphic Arts divestiture. But at roughly a $456M valuation, the market isn’t pricing in much success. If management delivers on its stated path toward robust double-digit earnings growth beginning in 2027, while aerospace, defense, hydrogen, space exploration, and SCBA demand continue strengthening, the current valuation could look very different over the next few years. $ASTS $LUNR $LMT $BA $PL $PLTR $SATL $NOC $VOO $CPSH $RDW $VELO $SIDU $FLY $FLYX $ #SPACEX That’s the disconnect worth watching.

English
7
7
58
4.5K
Hunters Allenn  retweetledi
Hunter Allen
Hunter Allen@HunterAllen4·
These are all semi & memory stocks I think we’re still relatively early on. Yes they are up but market cap wise just taking off. Yes I have posted dd on like 10 of these. $INTT $ASYS $COHU $NSYS $TRT $VECO $ADEA $AOSL $MRAM $POET $SILC $CEVA $QUIK $AIP $GSIT $CVV $MX
English
16
7
84
5.7K
Hunters Allenn  retweetledi
Hunter Allen
Hunter Allen@HunterAllen4·
$QXL +19% Come on x fam hit that sub button to support this research 🤝 I’m finally settled at work, let the reply’s commence. Have a great Thursday. Love you guys, appreciate you all 🔥 Another quantum name quietly making moves while most traders are focused on the larger players. Quantum X Labs just announced the launch of an integrated quantum computing program combining its patent-pending CliniQuantum platform with its proprietary Quantum Error Correction (QECC) Decoder technology. This is a much bigger development than the headline suggests. The biggest challenge facing the entire quantum computing industry isn’t building more qubits. It’s making them reliable. Quantum computers are incredibly powerful but also extremely noisy and error-prone. That’s why error correction is considered one of the most important technologies needed to unlock true commercial quantum computing. $QXL is now integrating: • CliniQuantum clinical trial analysis platform • Proprietary QECC Decoder technology • Hybrid GPU + Quantum environments • Multiple quantum computing platforms The goal is simple: Improve computational fidelity and move closer to scalable fault-tolerant quantum applications. This positions $QXL as more than just another quantum hardware story. They’re building an end-to-end quantum ecosystem that combines hardware, software, AI, error correction, and real-world industry applications under a single platform. Most quantum companies are focused on one piece of the puzzle. $QXL is attempting to address the entire stack, from quantum processing and error mitigation to specialized algorithms designed for commercial use cases. One area that stands out is healthcare. Their CliniQuantum platform focuses on clinical trial optimization, predictive modeling, patient selection, and biomedical data analysis. Considering pharmaceutical companies spend billions annually on drug development and clinical trials, even small improvements in efficiency could create massive economic value. Recent developments continue to build momentum: • Launched 50+ qubit neutral atom quantum computer • Targeting thousands of qubits by H1 2027 • Recently partnered with IQCC and Quantum Machines for decoder testing • Expanded scientific and technical advisory teams • Now validating software and decoder performance across multiple quantum platforms The market opportunity here is enormous. If Quantum X can demonstrate measurable improvements in accuracy, speed, or trial optimization, it opens the door for: • Pharmaceutical partnerships • CRO partnerships • Government contracts • Software licensing revenue • Quantum-as-a-Service offerings What I want to see next: Benchmark results showing decoder performance improvements Named partnerships with pharma companies Commercial pilot programs Additional patent grants Progress toward the 2027 qubit roadmap Keep in mind this remains a high-risk, early-stage quantum company. Revenue impact from today’s announcement is likely minimal near term. Execution is everything. But the company continues checking important boxes and advancing toward a differentiated position in one of the highest-value use cases for quantum computing. $LASE $QTEX $APLD $NVDA $AAOI $UMC $QBTS $QUBT $IONQ $LITE $SIVE $ASYS $ADEA $RGTI $TE $BE Quantum sector momentum remains strong and $QXL continues to add catalysts. Definitely one to keep on watch.
Hunter Allen@HunterAllen4

$QXL +5% 68M market cap. Testing 52 week highs. 50$ stock easy chilling. One of the smallest publicly traded quantum computing companies on Nasdaq and almost nobody is talking about it. ERROR CORRECTION IS THE REAL BOTTLENECK Early pivot. Early story. Early awareness. Repost. Bookmark. Subscribe for $1 to support. Most investors still associate the company with its former identity, Viewbix ($VBIX), a legacy video analytics and advertising platform. That company no longer exists in its original form. In March 2026, the company completed the acquisition of Quantum X Labs Ltd., an Israeli quantum technology company, and officially rebranded to Quantum X Labs with the new ticker $QXL effective April 30, 2026. The entire investment thesis changed. Today QXL is building a diversified quantum technology platform spanning: • Quantum Computing • Quantum Error Correction • Quantum Sensing • Quantum Navigation • Atomic Clocks • Drug Discovery • Quantum Cybersecurity • Nuclear Simulation • Transportation Optimization Most quantum companies focus on a single niche. QXL is attempting to build exposure across the entire quantum stack. The most important piece of the story may be its AI-powered Quantum Error Correction technology. For anyone new to quantum computing: Error correction is arguably the largest obstacle preventing practical large-scale quantum computers. QXL’s patent-pending transformer-based neural decoder attempts to solve that problem using AI. The company recently integrated $GOOG Quantum AI’s public surface-code dataset into its QECC pipeline, allowing training and benchmarking on real-world quantum error correction data rather than purely simulated environments. And now they’re pairing that software stack with their own hardware. On May 28, 2026, Quantum X Labs announced the launch of a 50+ physical qubit neutral-atom quantum computing platform. This is where the story gets interesting. WHY THE 50+ QUBIT LAUNCH MATTERS Many investors see “50 qubits” and immediately compare it to companies advertising hundreds or thousands of qubits. Quantum X Labs is attempting to solve both sides of the equation simultaneously. The platform utilizes: • Proprietary laser cooling • Dynamically reconfigurable optical tweezer arrays • High-fidelity atom loading • Extended coherence times • High-performance Rydberg-mediated quantum gates Management has publicly outlined a roadmap targeting thousands of physical qubits by the end of H1 2027. WHY NEUTRAL ATOMS MATTER Neutral atoms are increasingly viewed as one of the most scalable architectures in quantum computing. Advantages include: • Long coherence times • Dynamic reconfiguration • Large-scale array potential • Flexible connectivity • Reduced fabrication variability $QXL is simultaneously developing quantum sensing technologies with potentially nearer-term commercialization opportunities. QUANTUM GYROSCOPES Designed for GPS-denied environments. ATOMIC CLOCKS QXL recently filed a U.S. patent application related to compact quantum atomic clock technology. CLINIQUANTUM Potential use cases include: • Molecular modeling • Clinical trial optimization • Responder identification • Advanced biomedical simulations NUCLEAR QUANTUM Focused on reactor simulation, design optimization, safety analysis, and nuclear modeling. QUANTUMQ SECURITY Focused on protecting both classical and future quantum computing environments from emerging cyber threats. Another overlooked aspect of the story is the team. Recent additions include Professor Oren Kurland from Technion joining the Scientific Advisory Board. His expertise in artificial intelligence, information retrieval, and data science further strengthens the company’s AI-quantum convergence strategy. Q1 2026 revenue was approximately $353K. Core quantum revenue remains largely pre-commercial. $QXL $IONQ $QTEX $ATOM $WKEY $RGTI $IBM $DELL $NVDA $LAES $QUBT $QURE $QBTS $VOO $SMCI $TSSI

English
7
5
45
5.1K
Hunters Allenn  retweetledi
Hunter Allen
Hunter Allen@HunterAllen4·
$BFLY +22% PRE-MARKET Previously mentioned a couple weeks ago on breakout. One of the more interesting AI healthcare stories in the market right now. Butterfly Network ($BFLY) is the leader in handheld ultrasound technology through its proprietary Ultrasound-on-Chip platform, replacing traditional ultrasound hardware with semiconductor-based imaging. Today’s catalyst: Butterfly provided commentary on Midjourney Medical’s new full-body ultrasound scanner prototype. The scanner utilizes 40 Butterfly Ultrasound-on-Chip imaging modules under an existing licensing/co-development agreement announced in November 2025. That agreement alone carries up to $74M in potential payments over five years. This is a major validation of Butterfly’s growing “Embedded” business segment. The bigger picture: Midjourney’s scanner combines: • 40x Butterfly imaging modules • Massive AI reconstruction software • NVIDIA-powered compute infrastructure The system reportedly processes enormous data volumes, utilizing multiple servers and AI models to generate MRI-like imaging without radiation. $NVDA benefits as the compute backbone while $BFLY supplies the core imaging technology. Financially, $BFLY continues improving: • FY26 Revenue Guidance: $117M-$121M • Expected YoY growth: 20-24% • Q1 Revenue: ~$26.5M • Q2 Revenue Guidance: $27M-$31M Balance sheet remains one of the strongest among small-cap medical device names: • ~$140M Cash • $0 Debt • LTM Free Cash Flow: approximately -$20M At current burn rates, that’s roughly 7 years of runway. No immediate financing concerns. Another catalyst investors may be overlooking: Management has already disclosed plans for a next-generation probe launching in early 2027. Specs and pricing are expected to be released in late 2026. The new system will introduce tissue harmonic imaging, improving image quality and extending Butterfly’s technological lead versus competing handheld ultrasound platforms. Today at 12 PM ET, management is participating in TD Cowen’s Medical Devices Emerging Growth Call Series. Investors will be listening closely for updates on: • Enterprise adoption • AI subscription growth • Embedded licensing revenue • Midjourney partnership progress • Commercialization roadmap The Midjourney scanner itself remains early-stage and faces regulatory hurdles, but Butterfly wins regardless through licensing revenue and broader adoption of its semiconductor ultrasound platform. Market Cap: ~$1.5B Strong balance sheet. Growing recurring software revenue. Embedded licensing opportunities. AI healthcare exposure. Potential NVIDIA ecosystem connection. Definitely one to keep on watch. My subscription is $1/month. Let’s keep growing x fam. You’re not paying for buy/sell alerts — you’re supporting the time and research it takes to consistently find overlooked opportunities 99% of X don’t share. And more accounts to follow. Like these legends. @Wealth_WZRD @UnotheInvestor @cdettradess @M1CPW @InvestwithDoc @brandon_Invests @dusty_bull @kastriooot8 @Vance_Roberts5 @wallstnomads @QHCapital @CryptoSlider @Digital_Hus @Twills08 @notanotherquant @KeepitPassive @Jetson_Dad @PMooreTrades @gulVasikova @ZeekTyt @Btcbarbells @TheBTCKnight @ItsJamesHall @FinancePotentia @TapeVector @TrackNetWorth @ElijahColeman21 @LeifInvests @Options_Nirvana @investing_note @AfterHours1999 @couchpotradeo @leftlaneinvest @Noamneo_ @ThePoliteG @tradeconciencia @KieranT1000 @jonesrrrrrr @alecscrypto1 Most content will always stay free. Subscribers help me spend more time digging deeper, organizing ideas, and expanding research output.
Hunter Allen tweet media
English
20
14
79
7.5K
Hunters Allenn  retweetledi
Hunter Allen
Hunter Allen@HunterAllen4·
GM X FAM 🔥 Don’t miss these. Three very slept on stocks. $TRT $BTQ $RUM
Hunter Allen tweet mediaHunter Allen tweet mediaHunter Allen tweet media
English
48
10
100
8.5K
Hunters Allenn  retweetledi
Hunter Allen
Hunter Allen@HunterAllen4·
$NEOV IM BACK X FAM. Here’s a cool one to keep eyes on +23% One of the more interesting small-cap energy storage names starting to get attention. $NEOV isn’t just a residential battery company anymore. The story has shifted toward utility-scale BESS manufacturing, domestic energy infrastructure, and AI power demand. NeoVolta is building a vertically integrated U.S. battery storage platform with its Georgia manufacturing JV, positioning itself to benefit from growing demand from utilities, renewable projects, and AI data centers. Key numbers: • Market cap only ~$94M-$116M • TTM revenue ~$18.1M • FY2025 revenue grew 219% YoY to $8.43M • First 9 months FY2026 revenue reached $13.3M (+262% YoY) • Gross margins improving, reaching ~46% in Q3 FY2026 • Cash position around $11.5M with low debt levels • Needham recently initiated coverage with an $8 price target The biggest catalyst here is BESS. NeoVolta increased ownership of its Georgia manufacturing JV to 80% and is preparing for production ramp-up later this year. The facility is expected to have approximately 2 GWh of initial annual production capacity with the ability to expand further as demand grows. The headline deal investors are watching: • $200M LOI with Infinite Grid Capital • Approximately 1.1 GWh of battery storage deployments • Projects planned across West Texas, Puerto Rico, and PJM markets • Includes exposure to grid modernization and AI infrastructure power demand While the agreement remains non-binding, it represents the company’s first major utility-scale supply relationship and validates demand ahead of the Georgia manufacturing launch. Recent momentum also includes: • New commercial & industrial BESS products • Expansion beyond residential solar storage • Recognition as 2026 Energy Storage Company of the Year • Growing focus on FEOC-compliant U.S.-manufactured energy storage systems The company remains unprofitable today, reporting a TTM net loss of roughly $11.5M as it invests heavily in manufacturing capacity, R&D, and commercial expansion. But this is increasingly becoming a U.S. battery manufacturing and utility-scale energy storage story rather than simply a residential solar company. With AI data centers driving massive power demand, grid operators requiring long-duration storage solutions, and domestic manufacturing becoming a national priority, $NEOV sits at the intersection of several powerful themes.
Hunter Allen tweet mediaHunter Allen tweet media
English
16
11
75
7K
Hunters Allenn  retweetledi
Hunter Allen
Hunter Allen@HunterAllen4·
$GPUS +66% One of the hottest AI infrastructure names on the market right now. I’ve been watching $GPUS closely as it completes a full transition from Bitcoin mining into AI data centers, colocation, GPU compute, and humanoid robotics. The biggest catalyst? $GPUS announced advanced negotiations for a 20MW AI compute agreement at its Michigan campus. Management estimates the deal could generate over $1 BILLION in revenue over 20 years. If expanded to 32-52MW, the total opportunity could approach $2.5 BILLION. The Michigan campus is a massive asset: • 617,000 sq ft facility • 34.5 acres • Currently ~30MW of power capacity • Targeting 70MW within 20 months • Long-term potential of up to 340MW The company is converting over 100,000 sq ft of the campus specifically for AI infrastructure and GPU deployments. Another thing that caught my attention: $GPUS holds approximately 713.6 BTC worth about $47M plus roughly $40M in cash and restricted cash. That’s about $87M in liquid assets, representing roughly 73% of the company’s recent market capitalization. Revenue growth has also accelerated. Preliminary Q1 2026 revenue came in around $44M, up 76% YoY from approximately $25M. The company is also pursuing a unique robotics strategy through subsidiary Omnipresent Robotics. Production has begun on the first 30 OPR-R2 humanoid robots that will be deployed at the Michigan AI campus. Long-term plans call for more than 143 robots operating on-site, creating valuable real-world AI training data while supporting facility operations. Management believes AI infrastructure offers significantly higher margins than Bitcoin mining and intends to transition the Michigan site fully toward AI workloads. The bull case here is simple: AI demand continues exploding. Power is scarce. GPU capacity is scarce. Data center space is scarce. $GPUS is attempting to monetize all three while maintaining a sizable Bitcoin treasury on the balance sheet. Still a highly speculative microcap with volatility, dilution risk, and execution risk. But this is exactly the type of AI infrastructure story that retail traders have been chasing all year. Worth keeping on watch.
Hunter Allen tweet media
English
30
24
136
19.1K
Hunters Allenn  retweetledi
Hunter Allen
Hunter Allen@HunterAllen4·
How to become a millionaire by 2030. Follow & Subscribe to me 1$ Find stocks 99% x don’t talk about. $HQ +29% $SHAZ +15% $RXT +31% Add said stocks to WL. They all 10x. Find other alpha x accounts through me. Find financial freedom. Retire.
English
10
5
69
5K
Hunters Allenn  retweetledi
Hunter Allen
Hunter Allen@HunterAllen4·
$CUE +8% Why are biotech investors watching this one? The catalyst calendar is packed for H2 2026. CUE-221 (formerly Ascendant-221) This may be the most important near-term catalyst. Cue recently acquired exclusive global rights outside Greater China. The asset is already in Phase 2 development. Targets: • Chronic spontaneous urticaria (CSU) • Food allergy What makes it unique? Unlike traditional anti-IgE therapies, CUE-221 has a dual mechanism. It can: • Neutralize circulating IgE • Potentially suppress future IgE production through CD23 signaling Earlier studies showed: • Durable IgE suppression • Strong basophil inhibition • Encouraging safety profile • Clinical responses in CSU patients Upcoming: • China Phase 2 data readout in H2 2026 • Potential U.S. IND amendment • Potential global Phase 2b food allergy trial CUE-401 Another major catalyst. A bifunctional IL-2 / TGF-beta fusion protein designed to restore immune tolerance. Recent preclinical data showed: • Generation of antigen-specific regulatory T cells • Reduction of pathogenic immune responses • Activity in autoimmune gastritis models • Activity in graft-versus-host disease models • Durable responses after treatment Upcoming milestones: • IND submission planned H2 2026 • First-in-human Phase 1 study expected by year-end Additional catalyst: Boehringer Ingelheim collaboration • First optimization milestone achieved • $7.5M already received • Up to $345M milestone opportunity remains Add in the new CEO, stronger balance sheet, expanding pipeline and multiple upcoming data readouts and it’s easy to see why biotech investors are keeping this name on watchlists. Small cap biotech remains high risk, but there are several potential value-inflection events ahead. @TheFlowShark This is a paid post. Not financial advice. DISCLAIMER 🔗 tinyurl.com/ye2yj2nr Sector Peers: $NTLA $IOVA $BNTX $VKTX $CRSP $EDIT $BEAM $SANA $XBI $HIMS $NUVB $UNH $MRNA $MRK $UNH $OSCR $CLOV
Hunter Allen tweet mediaHunter Allen tweet mediaHunter Allen tweet mediaHunter Allen tweet media
English
4
8
26
2.2K
Hunters Allenn  retweetledi
Hunter Allen
Hunter Allen@HunterAllen4·
Reid says it’s time to launch for these stocks. To add to why I’m busy I have the kids at work lol I have dd posted for most of these. $HQ $FRMI $BESS $BTQ $TRT $QNT $DDD $RXT
Hunter Allen tweet media
English
25
3
58
2.9K
Hunters Allenn  retweetledi
Hunter Allen
Hunter Allen@HunterAllen4·
$CUE What makes Cue Biopharma different from hundreds of other biotech companies? Its entire platform is built around selective immune modulation. Most immune therapies activate or suppress broad portions of the immune system. That can create effectiveness but often comes with significant toxicity or unwanted side effects. Cue’s technology attempts to mimic the body’s natural immune signaling system. The goal: Expand and activate only the disease-relevant T cells while avoiding broad immune activation. Think precision-guided immunology. The platform is built around validated modular components that can be recombined into multiple therapies. This potentially allows: • Faster development • Lower development costs • Greater pipeline expansion opportunities Pipeline structure: CUE-100 Series • Clinical-stage oncology programs • Generated human safety and activity data • Validated the platform in patients CUE-400 Series • Regulatory T-cell induction • Designed to restore immune tolerance in autoimmune disease CUE-500 Series • Targeted B-cell depletion • Designed to selectively eliminate pathogenic B cells One of the most interesting programs is CUE-401. Preclinical data has shown: • Induction of FOXP3+ regulatory T cells • Reduction of inflammatory pathways • Durable efficacy in autoimmune disease models • Favorable tolerability in animal studies The company has also validated the platform through major partnerships including: • Boehringer Ingelheim • ImmunoScape Rather than betting on a single drug, investors are effectively getting exposure to a broader precision immunology platform spanning oncology, autoimmune disease and allergy. That’s what makes the story interesting. @TheFlowShark This is a paid post. Not financial advice. DISCLAIMER 🔗 tinyurl.com/ye2yj2nr Sector Peers: $NTLA $IOVA $BNTX $VKTX $CRSP $EDIT $BEAM $SANA $XBI $HIMS $NUVB $UNH $MRNA $MRK $OSCR $CLOV
Hunter Allen tweet media
English
6
4
24
1.9K
Hunters Allenn  retweetledi
Hunter Allen
Hunter Allen@HunterAllen4·
$CUE One of the biggest bullish developments here may actually be the people running the company. Cue completely upgraded its executive leadership and board during 2026 as it pivots into a clinical-stage autoimmune and allergy company. New CEO: Shao-Lee Lin, M.D., Ph.D. Her resume is stacked. • Founder and CEO of ACELYRIN • Took ACELYRIN public within 3 years • IPO valuation exceeded $2B • Raised more than $1B in capital • Built multiple clinical-stage programs Previous leadership roles include: • AbbVie • Gilead Sciences • Amgen • Horizon Therapeutics She contributed to development of blockbuster medicines including: • TEPEZZA • SKYRIZI • RINVOQ Education: • Chemical Engineering & Biochemistry (Rice University) • M.D. and Ph.D. (Johns Hopkins) The development team is equally impressive. Daniel Baker serves as Interim Chief Development Officer. He spent nearly 20 years at Johnson & Johnson/Janssen as VP of Immunology R&D. Programs he helped oversee led to more than 15 regulatory approvals globally including: • Remicade • Stelara • Simponi The board also added: Daniel Camardo • Former CEO of Athersys • Former President of Horizon Therapeutics U.S. • Over 30 years commercial leadership experience Viola Meehan • Former CFO of Vanqua Bio • Former VP of R&D Finance at AbbVie • More than 30 years of pharma finance experience For a company entering pivotal development stages, this is one of the strongest leadership refreshes I’ve seen in the small-cap biotech space. Management matters. @TheFlowShark This is a paid post. Not financial advice. DISCLAIMER 🔗 tinyurl.com/ye2yj2nr Sector Peers: $NTLA $IOVA $BNTX $VKTX $CRSP $EDIT $BEAM $SANA $XBI $HIMS $NUVB $UNH $MRNA $MRK $OSCR
Hunter Allen tweet mediaHunter Allen tweet media
English
12
4
30
2.3K
Hunters Allenn  retweetledi
Hunter Allen
Hunter Allen@HunterAllen4·
$CUE 19$ is support 30$ to breakout KEEP EYES ON HER 👀 One biotech name quietly improving nearly every major financial metric. Cue Biopharma is building a precision immunology company focused on autoimmune, inflammatory and allergic diseases while using partnerships to help fund development. Q1 2026 Highlights: • Revenue: $5.7M vs $0.4M YoY (+1,300%+) • Net loss: $5.2M vs $12.3M YoY • R&D expenses: $6.9M vs $8.5M YoY • G&A remained stable around $4.2M • Cash and equivalents: $16.4M as of March 31, 2026 Since quarter-end the balance sheet improved further: • Raised $27.6M net through a private placement • Received a $7.5M milestone payment from Boehringer Ingelheim • Added approximately $35M of additional liquidity after quarter-end The Boehringer partnership alone is significant: • $12M upfront payment • $7.5M milestone already achieved • Up to $345M in total milestone opportunities • Future royalty potential Unlike many development-stage biotechs, Cue is beginning to generate meaningful collaboration revenue while simultaneously reducing losses. The company has now transitioned from a pure cash-burning R&D story toward a partnership-supported clinical development model. With major catalysts expected throughout H2 2026, the strengthened balance sheet should allow advancement of CUE-221 and CUE-401 without immediate financing pressure. Definitely one to keep on watch. @TheFlowShark This is a paid post. Not financial advice. DISCLAIMER 🔗 tinyurl.com/ye2yj2nr Sector Peers: $NTLA $IOVA $BNTX $VKTX $CRSP $EDIT $BEAM $SANA $XBI $HIMS $NUVB $UNH $MRNA $MRK $COSM $CLOV
Hunter Allen tweet mediaHunter Allen tweet mediaHunter Allen tweet media
English
10
5
39
2.7K
Hunters Allenn  retweetledi
Hunter Allen
Hunter Allen@HunterAllen4·
Gm x fam gonna be busy today like I said last night. Hit that sub button to support. It’s 1$ Appreciate you all 🔥 $CELH +4% Citi put up a buy on $FIG @Wealth_WZRD
Hunter Allen tweet media
English
49
4
80
4K
Hunters Allenn  retweetledi
Hunter Allen
Hunter Allen@HunterAllen4·
Subscribe to me for 1$. I’m gonna be busy tomorrow so I had to put in the work today. If you didn’t get a reply well I tried. 😉 I will support you and shout you out if I see you making good posts and engaging. @cmsinvests is proof 300-10k @JFergistheman will be next 1.2-6k so far I give everything to the public mainly. But you get different ideas not 99% of x is talking about put on your radar. Support the research to finding new long term opportunities not all of x is on. Yes I miss a few but I’m doing this to build a community on here. New ideas New account shoutouts New friends Here’s a few more legends to follow too @Wealth_WZRD @InvestJourneyX @QuietGrowthClub @miko_invests @dividendbuff @PinguStacks @pulseandprofit @glocalinvestor @riverwolf0518 @heavyhitter2112 @MoMoMacro @CantoRobinHood @CapitalChr92373 @M1CPW @LincolnCarter0 @FckYrDbts @Dboybruh @Dividend_P @TQtradesNQ @XYZalerts @FinanceCari @seahorse_anton @mayaivanoff @athuinvests @wallstnomads @BullMarketBoss @wasianinvestor @ClubhouseGrowth @wealthby50 @financefraz @DorisDi3 @kurrensy_trades Also shoutout too @LeifInvests @Mapago9 THEY ARE BACKKKKKK Be the .1% LETS GO X FAM THANK YOU FOR 15k
Hunter Allen tweet media
English
60
20
147
14K